Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Equity Average (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Equity Average for 15 consecutive years, with $396.6 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 26.54% to $396.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $396.6 million through Dec 2025, down 26.54% year-over-year, with the annual reading at $432.9 million for FY2025, 20.1% down from the prior year.
  • Equity Average hit $396.6 million in Q4 2025 for Vanda Pharmaceuticals, down from $476.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $544.5 million in Q1 2024 to a low of $396.6 million in Q4 2025.
  • Historically, Equity Average has averaged $509.2 million across 5 years, with a median of $516.8 million in 2022.
  • Biggest five-year swings in Equity Average: grew 11.9% in 2021 and later fell 26.54% in 2025.
  • Year by year, Equity Average stood at $499.1 million in 2021, then grew by 4.47% to $521.4 million in 2022, then increased by 4.33% to $544.0 million in 2023, then decreased by 0.76% to $539.9 million in 2024, then dropped by 26.54% to $396.6 million in 2025.
  • Business Quant data shows Equity Average for VNDA at $396.6 million in Q4 2025, $476.2 million in Q3 2025, and $498.9 million in Q2 2025.